U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C37H53NO8
Molecular Weight 639.8186
Optical Activity UNSPECIFIED
Defined Stereocenters 10 / 10
E/Z Centers 2
Charge 0

SHOW SMILES / InChI
Structure of MOXIDECTIN

SMILES

[H][C@@]12OC\C3=C/C=C/[C@H](C)C\C(C)=C\C[C@@H]4C[C@@H](C[C@]5(C\C(=N/OC)[C@H](C)[C@H](O5)C(\C)=C\C(C)C)O4)OC(=O)[C@H](C=C(C)[C@H]1O)[C@@]23O

InChI

InChIKey=YZBLFMPOMVTDJY-LSGXYNIPSA-N
InChI=1S/C37H53NO8/c1-21(2)14-25(6)33-26(7)31(38-42-8)19-36(46-33)18-29-17-28(45-36)13-12-23(4)15-22(3)10-9-11-27-20-43-34-32(39)24(5)16-30(35(40)44-29)37(27,34)41/h9-12,14,16,21-22,26,28-30,32-34,39,41H,13,15,17-20H2,1-8H3/b10-9+,23-12+,25-14+,27-11+,38-31+/t22-,26-,28+,29-,30-,32+,33+,34+,36-,37+/m0/s1

HIDE SMILES / InChI
Molecular Formula C37H53NO8
Molecular Weight 639.8186
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 10 / 10
E/Z Centers 2
Optical Activity UNSPECIFIED

Approval Year

Unknown
86413
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:44:19 UTC 2023
Edited
by admin
on Sat Dec 16 16:44:19 UTC 2023
Record UNII
NGU5H31YO9
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MOXIDECTIN
GREEN BOOK   INN   MART.   MI   USAN   USP-RS  
INN   USAN  
Official Name English
MOXIDECTIN [ORANGE BOOK]
Common Name English
NSC-760424
Code English
MOXIDECTIN [MI]
Common Name English
ADVOCATE COMPONENT MOXIDECTIN
Brand Name English
MOXIDECTIN [MART.]
Common Name English
MOXIDECTIN [EMA EPAR VETERINARY]
Common Name English
moxidectin [INN]
Common Name English
MOXIDECTIN FOR VETERINARY USE [EP MONOGRAPH]
Common Name English
MOXIDECTIN [USAN]
Common Name English
MOXIDECTIN [USP MONOGRAPH]
Common Name English
Moxidectin [WHO-DD]
Common Name English
MOXIDECTIN COMPONENT OF ADVOCATE
Brand Name English
MOXIDECTIN [USP-RS]
Common Name English
CL 301,423
Code English
MILBEMYCIN B, 5-O-DEMETHYL-28-DEOXY-25-(1,3-DIMETHYL-1-BUTENYL)-6,28-EPOXY-23-(METHOXYIMINO)-,(6R,23E,25S(E))-
Common Name English
(6R,25S)-5-O-Demethyl-28-deoxy-25-[(E)-1,3-dimethyl-1-butenyl]-6,28-epoxy-23-oxomilbemycin B 23-(E)-(O-methyloxime)
Common Name English
CL-301,423
Code English
MOXIDECTIN [GREEN BOOK]
Common Name English
Classification Tree Code System Code
EMA VETERINARY ASSESSMENT REPORTS ADVOCATE [AUTHORISED]
Created by admin on Sat Dec 16 16:44:20 UTC 2023 , Edited by admin on Sat Dec 16 16:44:20 UTC 2023
WHO-VATC QP54AB02
Created by admin on Sat Dec 16 16:44:20 UTC 2023 , Edited by admin on Sat Dec 16 16:44:20 UTC 2023
WHO-VATC QP54AB52
Created by admin on Sat Dec 16 16:44:20 UTC 2023 , Edited by admin on Sat Dec 16 16:44:20 UTC 2023
CFR 21 CFR 556.426
Created by admin on Sat Dec 16 16:44:20 UTC 2023 , Edited by admin on Sat Dec 16 16:44:20 UTC 2023
CFR 21 CFR 520.1452
Created by admin on Sat Dec 16 16:44:20 UTC 2023 , Edited by admin on Sat Dec 16 16:44:20 UTC 2023
CFR 21 CFR 524.1450
Created by admin on Sat Dec 16 16:44:20 UTC 2023 , Edited by admin on Sat Dec 16 16:44:20 UTC 2023
CFR 21 CFR 522.1450
Created by admin on Sat Dec 16 16:44:20 UTC 2023 , Edited by admin on Sat Dec 16 16:44:20 UTC 2023
CFR 21 CFR 522.1451
Created by admin on Sat Dec 16 16:44:20 UTC 2023 , Edited by admin on Sat Dec 16 16:44:20 UTC 2023
CFR 21 CFR 524.1146
Created by admin on Sat Dec 16 16:44:20 UTC 2023 , Edited by admin on Sat Dec 16 16:44:20 UTC 2023
CFR 21 CFR 520.1454
Created by admin on Sat Dec 16 16:44:20 UTC 2023 , Edited by admin on Sat Dec 16 16:44:20 UTC 2023
FDA ORPHAN DRUG 316510
Created by admin on Sat Dec 16 16:44:20 UTC 2023 , Edited by admin on Sat Dec 16 16:44:20 UTC 2023
CFR 21 CFR 520.1453
Created by admin on Sat Dec 16 16:44:20 UTC 2023 , Edited by admin on Sat Dec 16 16:44:20 UTC 2023
EMA VETERINARY ASSESSMENT REPORTS ADVOCATE [AUTHORISED]
Created by admin on Sat Dec 16 16:44:20 UTC 2023 , Edited by admin on Sat Dec 16 16:44:20 UTC 2023
CFR 21 CFR 520.1451
Created by admin on Sat Dec 16 16:44:20 UTC 2023 , Edited by admin on Sat Dec 16 16:44:20 UTC 2023
EMA VETERINARY ASSESSMENT REPORTS ADVOCATE [AUTHORISED]
Created by admin on Sat Dec 16 16:44:20 UTC 2023 , Edited by admin on Sat Dec 16 16:44:20 UTC 2023
Code System Code Type Description
DRUG BANK
DB11431
Created by admin on Sat Dec 16 16:44:20 UTC 2023 , Edited by admin on Sat Dec 16 16:44:20 UTC 2023
PRIMARY
RXCUI
1047072
Created by admin on Sat Dec 16 16:44:20 UTC 2023 , Edited by admin on Sat Dec 16 16:44:20 UTC 2023
PRIMARY RxNorm
INN
6400
Created by admin on Sat Dec 16 16:44:20 UTC 2023 , Edited by admin on Sat Dec 16 16:44:20 UTC 2023
PRIMARY
NCI_THESAURUS
C73264
Created by admin on Sat Dec 16 16:44:20 UTC 2023 , Edited by admin on Sat Dec 16 16:44:20 UTC 2023
PRIMARY
CAS
113507-06-5
Created by admin on Sat Dec 16 16:44:20 UTC 2023 , Edited by admin on Sat Dec 16 16:44:20 UTC 2023
PRIMARY
DRUG CENTRAL
5286
Created by admin on Sat Dec 16 16:44:20 UTC 2023 , Edited by admin on Sat Dec 16 16:44:20 UTC 2023
PRIMARY
USAN
AA-72
Created by admin on Sat Dec 16 16:44:20 UTC 2023 , Edited by admin on Sat Dec 16 16:44:20 UTC 2023
PRIMARY
SMS_ID
100000080598
Created by admin on Sat Dec 16 16:44:20 UTC 2023 , Edited by admin on Sat Dec 16 16:44:20 UTC 2023
PRIMARY
WIKIPEDIA
MOXIDECTIN
Created by admin on Sat Dec 16 16:44:20 UTC 2023 , Edited by admin on Sat Dec 16 16:44:20 UTC 2023
PRIMARY
MESH
C027837
Created by admin on Sat Dec 16 16:44:20 UTC 2023 , Edited by admin on Sat Dec 16 16:44:20 UTC 2023
PRIMARY
ALANWOOD
moxidectin
Created by admin on Sat Dec 16 16:44:20 UTC 2023 , Edited by admin on Sat Dec 16 16:44:20 UTC 2023
PRIMARY
PUBCHEM
9832912
Created by admin on Sat Dec 16 16:44:20 UTC 2023 , Edited by admin on Sat Dec 16 16:44:20 UTC 2023
PRIMARY
NSC
760424
Created by admin on Sat Dec 16 16:44:20 UTC 2023 , Edited by admin on Sat Dec 16 16:44:20 UTC 2023
PRIMARY
MERCK INDEX
m7646
Created by admin on Sat Dec 16 16:44:20 UTC 2023 , Edited by admin on Sat Dec 16 16:44:20 UTC 2023
PRIMARY Merck Index
EPA CompTox
DTXSID5037577
Created by admin on Sat Dec 16 16:44:20 UTC 2023 , Edited by admin on Sat Dec 16 16:44:20 UTC 2023
PRIMARY
ChEMBL
CHEMBL2104415
Created by admin on Sat Dec 16 16:44:20 UTC 2023 , Edited by admin on Sat Dec 16 16:44:20 UTC 2023
PRIMARY
EVMPD
SUB09085MIG
Created by admin on Sat Dec 16 16:44:20 UTC 2023 , Edited by admin on Sat Dec 16 16:44:20 UTC 2023
PRIMARY
DAILYMED
NGU5H31YO9
Created by admin on Sat Dec 16 16:44:20 UTC 2023 , Edited by admin on Sat Dec 16 16:44:20 UTC 2023
PRIMARY
FDA UNII
NGU5H31YO9
Created by admin on Sat Dec 16 16:44:20 UTC 2023 , Edited by admin on Sat Dec 16 16:44:20 UTC 2023
PRIMARY
RS_ITEM_NUM
1448559
Created by admin on Sat Dec 16 16:44:20 UTC 2023 , Edited by admin on Sat Dec 16 16:44:20 UTC 2023
PRIMARY
LACTMED
Moxidectin
Created by admin on Sat Dec 16 16:44:20 UTC 2023 , Edited by admin on Sat Dec 16 16:44:20 UTC 2023
PRIMARY
Related Record Type Details
ATP-BINDING CASSETTE SUB-FAMILY G MEMBER 2
TRANSPORTER -> INHIBITOR
Structure of MOXIDECTIN
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
CYTOCHROME P450 3A4
METABOLIC ENZYME -> INDUCER
CYP3A4 expression was also induced by rifampin by a mean value of approximately 43-fold compared to vehicle control values
INDUCER
MAY BE CLINICALLY SIGNIFICANT
ONCHOCERCA VOLVULUS
TARGET ORGANISM->INHIBITOR
Structure of MOXIDECTIN
EXCRETED UNCHANGED
No human mass balance study was conducted due to long half-life. Feces: 2% dose within the first 72 hours after 8 mg dose;
Related Record Type Details
Structure of (6R,25S)-5-O-DEMETHYL-28-DEOXY-25-((E)-1,3-DIMETHYL-4-HYROXY-1-BUTENYL)-6,28-EPOXY-23-OXOMILBEMYCIN B 23-(E)-(O-METHYLOXIME)
METABOLITE -> PARENT
Structure of MOXIDECTIN, (O-DEMETHYL, 8-HYDROXYMETHYL)-
METABOLITE -> PARENT
Structure of 23-KETO NEMADECTIN
METABOLITE -> PARENT
Structure of MOXIDECTIN, 4-HYDROXYMETHYL-
METABOLITE -> PARENT
Structure of MOXIDECTIN, 8-HYDROXYMETHYL-
METABOLITE -> PARENT
Related Record Type Details
Structure of 2-DEHYDRO-4-HYDROMOXIDECTIN, (4S)-
IMPURITY -> PARENT
TEST A; sum of impurities E and F: not more than 1.7 times the area of the principal peak in the chromatogram obtained with reference solution (a) (1.7 per cent)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 5-O-(4-NITROBENZOYL)MOXIDECTIN
IMPURITY -> PARENT
TEST B
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 25-DES((1E)-1,3-DIMETHYLBUT-1-ENYL)-25-((1E)-1-METHYLBUT-1-ENYL)MOXIDECTIN
IMPURITY -> PARENT
TEST A
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 24-DESMETHYLMOXIDECTIN
IMPURITY -> PARENT
TEST A
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of MOXIDECTIN, (23Z)-
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of 25-DES((1E)-1,3-DIMETHYLBUT-1-ENYL)-25-((1E)-1-METHYLPROP-1-ENYL)MOXIDECTIN
IMPURITY -> PARENT
TEST A
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 5O-DESMETHYL-28-DEOXY-25-((1E)-1,3-DIMETHYLBUT-1-ENYL)-23-(METHOXYIMINO)MILBEMYCIN B, (23E,25S)-
IMPURITY -> PARENT
TEST A
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 2,5-DIDEHYDRO-5-DEOXYMOXIDECTIN
IMPURITY -> PARENT
TEST B; sum of impurities H and I: not more than the area of the principal peak in the chromatogram obtained with reference solution (a) (1.0 per cent)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 7-O-((METHYLSULFANYL)METHYL)MOXIDECTIN
IMPURITY -> PARENT
TEST B
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of DESMETHYL ETHYLMOXIDECTIN
IMPURITY -> PARENT
TEST A; sum of impurities E and F: not more than 1.7 times the area of the principal peak in the chromatogram obtained with reference solution (a) (1.7 per cent)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 23-DES(METHOXYIMINO)-23-((METHYLSULFANYL)METHOXY)MOXIDECTIN, (23S)-
IMPURITY -> PARENT
TEST B; sum of impurities H and I: not more than the area of the principal peak in the chromatogram obtained with reference solution (a) (1.0 per cent)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 2-EPI-MOXIDECTIN
IMPURITY -> PARENT
TEST A
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of MOXIDECTIN
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Cmax PHARMACOKINETIC DOSAGE
PHARMACOKINETIC
ROUTE OF ADMINISTRATION
PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC DOSAGE
PHARMACOKINETIC
ROUTE OF ADMINISTRATION
PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966